41.68k followers • 31 symbols Watchlist by Yahoo Finance
Follow this list to discover and track the stocks that were bought the most by hedge funds in the last quarter.
Curated by Yahoo Finance
Follow this list to discover and track the stocks that were bought the most by hedge funds in the last quarter.
Background
Yahoo Finance employs sophisticated algorithms to monitor and detect trends in the global financial markets. We bring these insights to you in the form of watchlists.
Find other winning investment ideas with the Yahoo Finance Screener.
How are these weighted?The stocks in this watchlist are weighted equally.
Watchlist | Change today | 1-month return | 1-year return | Total return |
---|---|---|---|---|
Most bought by hedge funds | +1.17% | - | - | - |
^GSPC | +0.03% | +3.71% | +26.17% | +5605.42% |
Symbol | Company name | Last price | Change | % change | Market time | Volume | Avg vol (3-month) | Market cap |
---|---|---|---|---|---|---|---|---|
WMT | Walmart Inc. | 65.04 | -0.34 | -0.52% | 4:00 pm GMT-4 | 13.28M | 16.28M | 524.21B |
BAC | Bank of America Corporation | 39.32 | -0.38 | -0.96% | 4:00 pm GMT-4 | 25.89M | 37.97M | 307.50B |
PFE | Pfizer Inc. | 28.3 | -0.58 | -2.01% | 4:01 pm GMT-4 | 32.26M | 42.19M | 160.36B |
T | AT&T Inc. | 17.27 | -0.23 | -1.31% | 4:00 pm GMT-4 | 23.94M | 34.93M | 123.83B |
FCX | Freeport-McMoRan Inc. | 53.63 | +2.10 | +4.08% | 4:00 pm GMT-4 | 14.91M | 15.89M | 77.04B |
NU | Nu Holdings Ltd. | 12.18 | +0.45 | +3.84% | 4:00 pm GMT-4 | 30.29M | 23.57M | 58.23B |
PCG | PG&E Corporation | 18.22 | -0.24 | -1.30% | 4:00 pm GMT-4 | 9.72M | 13.09M | 47.64B |
F | Ford Motor Company | 11.68 | -0.48 | -3.95% | 4:00 pm GMT-4 | 56.29M | 49.37M | 46.41B |
CPNG | Coupang, Inc. | 22.81 | +0.46 | +2.06% | 4:00 pm GMT-4 | 7.20M | 14.26M | 40.78B |
VST | Vistra Corp. | 106.2 | +4.10 | +4.02% | 4:00 pm GMT-4 | 7.99M | 7.90M | 36.90B |
NOK | Nokia Oyj | 3.87 | +0.02 | +0.52% | 4:01 pm GMT-4 | 10.91M | 14.78M | 21.40B |
CCL | Carnival Corporation & plc | 15.65 | +0.52 | +3.44% | 4:00 pm GMT-4 | 27.04M | 30.10M | 20.50B |
TEVA | Teva Pharmaceutical Industries Limited | 16.76 | +0.16 | +0.96% | 4:00 pm GMT-4 | 6.68M | 9.94M | 18.98B |
AES | The AES Corporation | 21.13 | +0.22 | +1.05% | 4:00 pm GMT-4 | 6.54M | 9.56M | 15.02B |
JNPR | Juniper Networks, Inc. | 34.42 | -0.27 | -0.78% | 4:00 pm GMT-4 | 1.24M | 3.13M | 11.19B |
X | United States Steel Corporation | 36.82 | +0.91 | +2.53% | 4:00 pm GMT-4 | 3.71M | 4.11M | 8.28B |
SWN | Southwestern Energy Company | 7.44 | +0.05 | +0.68% | 4:00 pm GMT-4 | 9.47M | 13.33M | 8.21B |
ADT | ADT Inc. | 7.14 | -0.08 | -1.11% | 4:00 pm GMT-4 | 3.57M | 6.43M | 6.50B |
RIG | Transocean Ltd. | 6.11 | +0.34 | +5.89% | 4:00 pm GMT-4 | 19.38M | 17.97M | 5.01B |
ALIT | Alight, Inc. | 7.9 | -0.29 | -3.54% | 4:00 pm GMT-4 | 5.56M | 5.59M | 4.54B |
NYCB | New York Community Bancorp, Inc. | 3.3 | -0.03 | -0.90% | 4:00 pm GMT-4 | 9.48M | 30.52M | 2.71B |
DNA | Ginkgo Bioworks Holdings, Inc. | 0.6249 | -0.04 | -5.48% | 4:00 pm GMT-4 | 69.25M | 39.96M | 1.38B |
CATX | Perspective Therapeutics, Inc. | 1.56 | +0.06 | +4.00% | 4:00 pm GMT-4 | 13.20M | 5.61M | 971.30M |
TELL | Tellurian Inc. | 0.5608 | +0.04 | +8.41% | 4:00 pm GMT-4 | 19.62M | 35.17M | 468.96M |
FATE | Fate Therapeutics, Inc. | 3.54 | +0.02 | +0.57% | 4:00 pm GMT-4 | 1.69M | 2.57M | 402.97M |
ESPR | Esperion Therapeutics, Inc. | 2.1 | -0.03 | -1.41% | 4:00 pm GMT-4 | 4.51M | 7.43M | 397.87M |
CYBN | Cybin Inc. | 0.3499 | -0.01 | -1.74% | 4:00 pm GMT-4 | 2.64M | 5.22M | 265.82M |
RGLS | Regulus Therapeutics Inc. | 2.045 | +0.03 | +1.24% | 4:00 pm GMT-4 | 525.18k | 3.32M | 133.88M |
ACET | Adicet Bio, Inc. | 1.56 | +0.07 | +4.70% | 4:00 pm GMT-4 | 673.02k | 1.30M | 128.19M |
TPHS | Trinity Place Holdings Inc. | 0.151 | +0.01 | +11.03% | 3:59 pm GMT-4 | 7.24M | 2.91M | 9.67M |
While Nvidia continued to drive the Nasdaq higher, the Dow undercut support. Hot IPO Cava fell late on earnings.
TORONTO, May 29, 2024--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, today announced that Amir Inamdar, MBBS, DNB (Psych), MFPM, Cybin’s Chief Medical Officer, and Ellen James, Ph.D., Cybin’s Director, Clinical Development, will participate at the Interdisciplinary Conference on Psychedelic Res
These two giants are finally going head to head.